← 홈

난소암

353개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 353개
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 2

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 ACTIVE
ADCBiologicstaleBristol-Myers SquibbPhase 2

MORAb-202 (MORAb-202)

Carcinoma, Non-Small-Cell Lung · Neoplasms, Ovarian

#NeoplasmsOvarian#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 20%임상시험 4상태 DISCONTINUED
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

AZD5335 (AZD5335)

Epithelial Ovarian Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
CGTBiologicstaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 3상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

DNIB0600A (DNIB0600A)

Non-Squamous Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer, Ovarian Canc

#Non-SmallCellLungCancerOvarianCa#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib Hydrochloride (Defactinib Hydrochloride)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 3상태 RECRUITING
AntibodystaleSutro Biopharma, Inc.Phase 3

Luveltamab tazevibulin (Luveltamab tazevibulin)

Ovarian Cancer; Epithelial Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase3#항체#면역항체+3
임상시험 3상태 DISCONTINUED
AntibodyRochePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+carboplatin±bevacizumab)

Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 3상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleTORL Biotherapeutics, LLCPhase 1

TORL-1-23 (TORL-1-23)

Advanced Solid Tumor; Ovarian Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
CGTBiologicstaleTmunity Therapeutics, a wholly …Phase 1

huCART-meso cells (huCART-meso cells)

Lung Adenocarcinoma; Ovarian Cancer · Pancreatic Cancer

#PancreaticCancer#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 0%임상시험 3상태 DISCONTINUED
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
CGTBiologicPeking UniversityPhase 1

B7H3 CAR-γδT cells (B7H3 CAR-γδT cells)

Advanced Solid Tumors; Ovarian Cancers · Advanced Solid Tumors

#AdvancedSolidTumors#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE

7 / 18 페이지

← 이전다음 →